Tempest Therapeutics is a technology company.
Tempest Therapeutics has raised $70.0M across 1 funding round.
Tempest Therapeutics has raised $70.0M in total across 1 funding round.
Tempest Therapeutics has raised $70.0M in total across 1 funding round.
Tempest Therapeutics's investors include F-Prime Capital Partners, Anthony Philippakis, The Column Group, Versant Ventures.
Tempest Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics that target cancer by combining direct tumor killing with immune-mediated mechanisms.[1][2][3] It focuses on oncology immunotherapies addressing unmet needs in solid tumors, with lead candidates TPST-1120 (a selective PPARα antagonist for hepatocellular carcinoma and other solid tumors) and TPST-1495 (a selective EP2/4 antagonist for solid tumors and familial adenomatous polyposis).[1][2] The company serves cancer patients by modulating the tumor microenvironment to enhance immune responses, currently generating no revenue as it advances candidates through clinical trials.[1][3]
Tempest's growth momentum includes positive Phase 1 data for TPST-1120 (amezalpat) showing survival benefits in first-line HCC, even in challenging subpopulations like PD-L1 negative or β-catenin mutated disease, with plans for a pivotal study and expansion beyond HCC.[2] TPST-1495 is slated for a Phase 2 study in FAP patients in 2024, funded by the National Cancer Institute.[2]
Tempest Therapeutics operates as a clinical-stage biopharma entity in Brisbane, California, with a focus on novel oncology therapeutics derived from scientific insights into tumor-immune interactions.[2][3] While specific founding details like year or founders are not detailed in available sources, the company's emergence centers on leveraging established and novel science to develop small molecules that improve cancer standard of care without platform biases.[2] Early traction stems from advancing TPST-1120 and TPST-1495 into clinical stages, with pivotal Phase 1 results for TPST-1120 in HCC driving momentum toward larger trials.[1][2]
Tempest stands out in oncology through targeted small molecule approaches that address both tumor cells and immune suppression:
Tempest rides the wave of immuno-oncology innovation, where modulating the tumor microenvironment is key to overcoming resistance in solid tumors amid stagnant progress in traditional therapies.[2] Timing aligns with rising demand for therapies effective in immune-cold tumors (e.g., HCC, β-catenin mutated cases), fueled by market forces like checkpoint inhibitor limitations and NCI support for prevention trials.[1][2] By developing first/best-in-class small molecules, Tempest influences the ecosystem through data validating dual tumor-immune targeting, potentially expanding immunotherapy efficacy and attracting partnerships in the $100B+ oncology market.[1][2]
Tempest is poised for inflection with TPST-1120's pivotal HCC trial and TPST-1495's NCI-backed Phase 2, potentially unlocking readouts in 2025-2026 amid immuno-oncology tailwinds.[2] Trends like combination therapies and microenvironment modulation will shape its path, with expansion beyond HCC/FAP amplifying impact if survival signals hold. Its influence could grow via trial successes, positioning it as a nimble player in targeted cancer care—harnessing immune power to redefine oncology outcomes, much like its core mission promises.[1][2]
Tempest Therapeutics has raised $70.0M across 1 funding round. Most recently, it raised $70.0M Series B in March 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2018 | $70.0M Series B | F-Prime Capital Partners, Anthony Philippakis, The Column Group, Versant Ventures |